Novel Bradykinin Analogues Modified in the N-Terminal Part of the Molecule with a Variety of Acyl Substituents

Overview

Journal Int J Pept Res Ther

Publisher Springer

Date 2012 May 18

PMID 22593719

Citations 1

Authors

Malgorzata Sleszynska

Tomasz H Wierzba

Krzysztof Malinowski

Tereza Tumova

Bernard Lammek

Jirina Slaninova

Adam Prahl

Affiliations

Soon will be listed here.

Abstract

In the current work we present some pharmacological characteristics of ten new analogues of bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) modified in the N-terminal part of the molecule with a variety of acyl substituents. Of the many acylating agents used previously with B(2) receptor antagonists, the following residues were chosen: 1-adamantaneacetic acid (Aaa), 1-adamantanecarboxylic acid (Aca), 4-tert-butylbenzoic acid (t-Bba), 4-aminobenzoic acid (Aba), 12-aminododecanoic acid (Adc), succinic acid (Sua), 4-hydroxybenzoic acid, 4-hydroxy-3-methoxybenzoic acid, 3-(4-hydroxyphenyl)propionic acid and 6-hydroxy-2-naphthoic acid. Biological activity of the compounds was assessed in the in vivo rat blood pressure test and the in vitro rat uterus test. Surprisingly, N-terminal substitution of the bradykinin peptide chain itself with aforementioned groups resulted in antagonists of bradykinin in the pressor test and suppressed agonistic potency in the uterotonic test. These interesting findings need further studies as they can be helpful for designing more potent B(2) receptor blockers.

Citing Articles

Bradykinin and Neurotensin Analogues as Potential Compounds in Colon Cancer Therapy.

Szarynska M, Olejniczak-Keder A, Podplonska K, Prahl A, Ilowska E Int J Mol Sci. 2023; 24(11).

PMID: 37298595 PMC: 10253536. DOI: 10.3390/ijms24119644.

References

Ueno A, Oh-Ishi S . Roles for the kallikrein-kinin system in inflammatory exudation and pain: lessons from studies on kininogen-deficient rats. J Pharmacol Sci. 2003; 93(1):1-20. DOI: 10.1254/jphs.93.1. View

Holton P . A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br J Pharmacol Chemother. 1948; 3(4):328-34. PMC: 1509859. DOI: 10.1111/j.1476-5381.1948.tb00396.x. View

Odya C, Goodfriend T, Pena C . Bradykinin receptor-like binding studied with iodinated analogues. Biochem Pharmacol. 1980; 29(2):175-85. DOI: 10.1016/0006-2952(80)90326-3. View

Steranka L, Manning D, Dehaas C, Ferkany J, Borosky S, Connor J . Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc Natl Acad Sci U S A. 1988; 85(9):3245-9. PMC: 280181. DOI: 10.1073/pnas.85.9.3245. View

Moreau M, Garbacki N, Molinaro G, Brown N, Marceau F, Adam A . The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci. 2005; 99(1):6-38. DOI: 10.1254/jphs.srj05001x. View

Boels K, Schaller H . Identification and characterisation of GPR100 as a novel human G-protein-coupled bradykinin receptor. Br J Pharmacol. 2003; 140(5):932-8. PMC: 1574110. DOI: 10.1038/sj.bjp.0705521. View

Bascands J, Schanstra J, Couture R, Girolami J . [Bradykinin receptors: towards new pathophysiological roles]. Med Sci (Paris). 2003; 19(11):1093-100. DOI: 10.1051/medsci/200319111093. View

Lammek B, Wang Y, Gavras I, Gavras H . A novel bradykinin antagonist with improved properties. J Pharm Pharmacol. 1991; 43(12):887-8. DOI: 10.1111/j.2042-7158.1991.tb03205.x. View

Labudda-Dawidowska O, Wierzba T, Prahl A, Kowalczyk W, Gawinski L, Plackova M . New bradykinin analogues modified in the C-terminal part with sterically restricted 1-aminocyclohexane-1-carboxylic acid. J Med Chem. 2005; 48(25):8055-9. DOI: 10.1021/jm0580353. View

10.

Dawidowska O, Prahl A, Wierzba T, Nowakowski L, Kowalczyk W, Slaninova J . New acylated bradykinin analogues: effect on rat blood pressure and rat uterus. J Pept Sci. 2005; 11(7):436-9. DOI: 10.1002/psc.646. View

11.

Labudda O, Wierzba T, Sobolewski D, Sleszynska M, Gawinski L, Plackova M . New bradykinin analogues acylated on the N-terminus: effect on rat uterus and blood pressure. Acta Biochim Pol. 2007; 54(1):193-8. View

12.

Kenakin T . Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 2001; 15(3):598-611. DOI: 10.1096/fj.00-0438rev. View

13.

Lefkowitz R . The superfamily of heptahelical receptors. Nat Cell Biol. 2000; 2(7):E133-6. DOI: 10.1038/35017152. View

14.

Borkowski J, Ransom R, Seabrook G, Trumbauer M, Chen H, Hill R . Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem. 1995; 270(23):13706-10. DOI: 10.1074/jbc.270.23.13706. View

15.

Prahl A . Modifications in the bradykinin main chain are not necessary for antagonistic activity in rat blood pressure assay. J Pept Sci. 2006; 13(3):206-10. DOI: 10.1002/psc.830. View

16.

Milan A, Mulatero P, Williams T, Carra R, Schiavone D, Martuzzi R . Bradykinin B2 receptor gene (-58T/C) polymorphism influences baroreflex sensitivity in never-treated hypertensive patients. J Hypertens. 2005; 23(1):63-9. DOI: 10.1097/00004872-200501000-00014. View

17.

Hock F, Wirth K, Albus U, Linz W, Gerhards H, Wiemer G . Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991; 102(3):769-73. PMC: 1917958. DOI: 10.1111/j.1476-5381.1991.tb12248.x. View

18.

Rhaleb N, Telemaque S, Rouissi N, Dion S, Jukic D, Drapeau G . Structure-activity studies of bradykinin and related peptides. B2-receptor antagonists. Hypertension. 1991; 17(1):107-15. DOI: 10.1161/01.hyp.17.1.107. View

19.

MUNSICK R . Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology. 1960; 6:451-7. DOI: 10.1210/endo-66-3-451. View

20.

Vavrek R, Stewart J . Competitive antagonists of bradykinin. Peptides. 1985; 6(2):161-4. DOI: 10.1016/0196-9781(85)90033-6. View